Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8128255 | 0.86 | PTGS2 (0.41) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL9176049 | 0.85 | PTGS1 (0.50) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL8123794 | 0.85 | SIGMAR1 (0.41) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL1131597 | 0.82 | PTGS1 (0.56) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL1114511 | 0.80 | PTGS1 (0.47) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL5174938 | 0.79 | PTGS1 (0.54) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL2745550 | 0.79 | GFER (0.42) | ESR1HTR2ABLMALDH1A1 | |
| SCHEMBL97239 | 0.79 | TRPA1 (0.36) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL5024911 | 0.78 | SIGMAR1 (0.49) | PTGS2PTGS1LMNACYP2C9AKR1C3 | |
| SCHEMBL9045813 | 0.78 | PTGS1 (0.45) | PTGS2PTGS1LMNACYP2C9AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194716-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-08-31 | — | — | US | claimed |
| US-6770621-B2 | GLYCOPEPTIDE WITH TWO OR MORE CARBOXY GROUPS AT THE C-TERMINUS, NOT INCLUDING SPECIFIED TEICOPLANINS; TREATING BACTERIAL DISEASES | THERAVANCE, INC. | 2004-08-03 | — | — | US | claimed |
| US-20020055464-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2002-05-09 | — | — | US | claimed |
| WO-2001083520-A2 | POLYACID GLYCOPEPTIDE DERIVATIVES | THERAVANCE,INC (US) | 2001-11-08 | — | — | WO | claimed |
| US-11718758-B2 | Aqueous dispersion of colored particles | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-3725854-B1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL CO (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-20210071006-A1 | AQUEOUS DISPERSION OF COLORED PARTICLES | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3725854-A1 | COLORED PARTICLE AQUEOUS DISPERSION | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3444304-A1 | POLYFUNCTIONAL POLYMERIZABLE COMPOUND AND COLORED COMPOSITION | FUJIFILM Wako Pure Chemical Corporation (JP) | 2019-02-20 | — | — | EP | disclosed |
| CN-108473784-A | Polyfunctional polymerizable compound and coloring composition | 富士胶片和光纯药株式会社 | 2018-08-31 | — | — | CN | disclosed |
| US-7244705-B2 | Polyacid glycopeptide derivatives | THERAVANCE, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20060194716-A1 | Polyacid glycopeptide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2006-08-31 | — | — | US | disclosed |
| EP-0717742-B1 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5780633-A | Process for the preparation of indolizine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-14 | — | — | US | disclosed |
| CN-1130907-A | Process for preparation of indolizine derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-09-11 | — | — | CN | disclosed |
| EP-0717742-A1 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007279-A2 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-16 | — | — | WO | disclosed |
| US-5334716-A | Preventing testosteron 5a-reductase mediated diseases; alopecia, acne, prostatism | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-02 | — | — | US | disclosed |
| CN-1067893-A | Hete rocyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-01-13 | — | — | CN | disclosed |
| EP-0519353-A2 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055464-A1 | Polyacid glycopeptide derivatives | B3GAT3, GYPA, MGAT3 | PTGS2 3089/4885PTGS1 3939/4885LMNA 4186/4885 |
| US-20060194716-A1 | Polyacid glycopeptide derivatives | B3GAT3, NGLY1, DNPEP | PTGS2 4044/4885PTGS1 4006/4885LMNA 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.